Femme et Homme
- | Pays :
- India
- | Organes : -
- | Spécialités : -
Extrait
The present clinical study will assess the immunogenicity as the primary objective and the reactogenicity as the secondary objective of Aventis Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 6, 10 and 14 weeks of age followed by a booster dose during the second year of life. Safety: This study will describe the safety after each dose of the primary series of the study's combined vaccine (Pentaxim™).
Critère d'inclusion
- Diphtheria ,TETANUS ,Polio ,Pertussis ,Haemophilus Infections